ISTA (ISTA) to Continue Review of Strategic Options
Tweet
Share
E-mailGet Alerts ISTA Hot Sheet
Join SI Premium – FREE
The Board of Directors of ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today reiterated its commitment to maximizing shareholder value and said it will continue its previously announced review of all strategic options available to the Company. The Board issued its statement in response to a press release from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announcing that Valeant had withdrawn its unsolicited proposal to acquire ISTA.
ISTA's review of its strategic options, which the Company publicly announced on December 16, 2011, is advancing expeditiously and in a manner consistent with the Board's fiduciary responsibilities. ISTA is currently in dialogue with a number of parties that have expressed an interest in pursuing a strategic transaction and remains committed to maximizing shareholder value.
ISTA's review of its strategic options, which the Company publicly announced on December 16, 2011, is advancing expeditiously and in a manner consistent with the Board's fiduciary responsibilities. ISTA is currently in dialogue with a number of parties that have expressed an interest in pursuing a strategic transaction and remains committed to maximizing shareholder value.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Holcim to acquire Fermacell from James Hardie for EUR 840M
- Swarmer invests in Erik Prince-led Vectus Air Defense Systems
- Questor Technology signs LOI to acquire Emission Rx for up to C$3M
Create E-mail Alert Related Categories
Hot M&A, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
